# Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.

> **NCT02546674** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 171 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT02546674
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-18
- **Primary completion:** 2021-02-23
- **Final completion:** 2021-03-25
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546674, "Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02546674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*